• 1. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 2. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 3. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Butanoic Acid, 2-Amino-4-(S-Butylsulfonimidoyl)-, [S-(R*,S*)]- (9CI): A Comprehensive Overview

Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, [S-(R*,S*)]- (9CI), also known by its CAS registry number CAS No. 113158-69-3, is a complex organic compound with significant potential in various fields of chemistry and pharmacology. This compound is characterized by its unique structure, which includes a butanoic acid backbone with an amino group at the second position and a sulfonimidoyl group at the fourth position. The stereochemistry of the molecule is specified as [S-(R*,S*)], indicating a specific configuration that is crucial for its biological activity and applications.

The synthesis of this compound involves advanced organic chemistry techniques, including multi-step reactions and precise stereochemical control. Recent studies have highlighted the importance of such compounds in drug discovery, particularly in the development of bioactive molecules with specific therapeutic targets. The presence of the sulfonimidoyl group introduces unique electronic and steric properties to the molecule, making it a promising candidate for various biochemical interactions.

One of the most intriguing aspects of CAS No. 113158-69-3 is its potential application in medicinal chemistry. Researchers have explored its ability to act as a scaffold for designing new drugs targeting specific enzymes or receptors. For instance, recent findings suggest that this compound may exhibit inhibitory activity against certain kinases, which are key players in various disease pathways, including cancer and inflammatory disorders.

In addition to its pharmacological applications, this compound has also been studied for its role in materials science. The sulfonimidoyl group imparts hydrophilic properties to the molecule, making it suitable for applications in polymer chemistry or as a component in advanced materials with tailored functionalities. Recent advancements in green chemistry have also led to investigations into more sustainable methods for synthesizing this compound, reducing its environmental footprint while maintaining its high purity and bioavailability.

The stereochemistry of Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, [S-(R*,S*)]- (9CI) plays a pivotal role in determining its biological activity. Stereoisomers can exhibit vastly different behaviors in biological systems, and the specific configuration of this compound has been shown to enhance its binding affinity to target proteins. This makes it an ideal candidate for enantioselective synthesis techniques, ensuring that only the desired stereoisomer is produced during manufacturing.

Recent research has also delved into the metabolic pathways of this compound within living organisms. Understanding how it is absorbed, distributed, metabolized, and excreted is essential for evaluating its safety and efficacy as a potential therapeutic agent. Studies using advanced analytical techniques such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy have provided valuable insights into its pharmacokinetics and pharmacodynamics.

Furthermore, computational chemistry approaches have been employed to predict the behavior of this compound under various conditions. Molecular docking studies have revealed potential binding sites on target proteins, providing a theoretical basis for experimental validation. These computational models are invaluable for optimizing the compound's structure to improve its therapeutic index while minimizing adverse effects.

In conclusion, CAS No. 113158-69-3, or Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, [S-(R*,S*)]- (9CI), represents a cutting-edge molecule with diverse applications across multiple disciplines. Its unique structure, stereochemistry, and bioactivity make it a focal point for ongoing research efforts aimed at harnessing its full potential in drug discovery and materials science.

• 21752-32-9(L-Methionine S-Sulfoximine)
• 5072-26-4(DL-Buthionine-(S,R)-sulfoximine)
• 15985-39-4(L-Methionine-DL-sulfoximine)
• 21752-31-8(L-Methionine R-Sulfoximine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)